HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.
Stocks · News reference
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, SPCX, KC, WELL, KYNB have coverage initiated.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — KYNTRA BIO, INC. (KYNB)
Filed: 2026-08-31 AccNo: 0001193125-26-377059 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50
Kyntra Bio
Sysco's Fiscal 2027 Outlook Puts AI Cost Savings in the Spotlight
Sysco Corporation projects fiscal 2027 sales growth of 6-7% to ~$90B and adjusted EPS growth of 9-11%, driven by AI-enabled productivity initiatives expected to deliver $100M in cost savings. However, the company's outlook depends on stable restaurant traffic and modest inflation, with execution risk around converting planned savings into sustained margin expansion while continuing infrastructure investments.
Mark Kelly Asks Public To Help NASA Identify Health Risks for Future Moon Missions: 'Science Is About Asking Questions'
Mark Kelly urges the public to suggest health research questions, data needs and technologies for NASA’s future long-duration Moon missions.